162/91 ALCOHOL monograf.a - Plan Nacional sobre drogas

Niveles en sangre
Sustancia Terapéuticos o normales Tóxicos Letales
mgr% µg/ml mgr% µg/ml mgr% µg/ml
Escopolamina 0,00003-0,0019 0,0003-0,019 - - 0,189 1,89
Ketamina 0,02-0,63 0,2-6,3 - - - -
MDA - - - - 0,18-2,6 1,8-26
Metanfetamina 0,001-0,005 0,01-0,05 0,06-0,5 0,6-5,0 >1 >10
Meperidina 0,007-0,080 0,07-0,80 0,5 5 0,8-2,0 8-20
Metilfentanil - - - - 0,0002-0,0011 0,002-0,011
PMA - - - - 0,02-0,49 0,2-4,9
PCP - - 0,0007- 0,007-0,24 0,1-0,5 1-5
0,024
Propilhexedrina 0,001 0,01 - - 0,2-0,3 2-3
Propoxifeno 0,023-0,107 0,23- 1,07 0,03-0,06 0,3-0,6 0,1-1,7 1-17
Pseudoefedrina 0,05-0,077 0,5-0,77 - - 1,9 19
REFERENCIAS
1. Albertson TE, Derlet RW, Van Hoozen BE.
Methamphetamine and the expanding complications
of amphetamines. West J Med
1999;170: 214-219.
2. Bermejo-Barrera P, Moreda-Pineiro A, Moreda-
Pineiro J, Bermejo-Barrera A, Bermejo-Barrera
AM. A study of illicit cocaine seizure classification
by pattern recognition techniques applied
to metal data. J Forensic Sci 1999; 44: 270-
274.
3. Burnett LB, Adler J. Toxicity, cocaine. Emedicine,
July 26, 2002
4. Camí J. Farmacologia y toxicidad de la
MDMA (Extasis). Barcelona: Ediciones en
Neurociencias, 1995.
5. Chiarotti M, Marsili R, Moreda-Pineiro A. Gas
chromatographic-mass spectrometric analysis
of residual solvent trapped into illicit cocaine
exhibits using head-space solid-phase microextraction.
J Chromatogr B Analyt Technol Biomed
Life Sci 2002; 772: 249-256.
6. Cunningham EE, Venuto RC, Zielezny MA.
Adulterants in heroin/cocaine: implications concerning
heroin-associated nephropathy. Drug
Alcohol Depend 1984; 14: 19-22.
7. Denborough MA, Hopkinson KC. Dantrolene
and “ecstasy”. Med J Aust 1997; 166: 165-166.
8. Derlet R, Albertson T. Toxicity, Methamphetamine.
Emedicine, January 22, 2002.
9. Dominguez E, Infante F, Luna A. Micocontamination
of illicit samples of heroin and cocaine
as indicator of adulteration. J Forensic Sci
1991; 36: 844-856.
10. Eisner B. Extasis: historia del MDMA. Barcelona:
Ediciones Obelisco, 1995.
11. Fucci N, De Giovanni N. Adulterants encountered
in the illicit cocaine market. Forensic Sci
Int 1998; 95: 247-252.
12. George AJ. Central nervous system stimulants.
Baillieres Best Pract Res Clin Endocrinol
Metab 2000; 14: 79-88.
13. Gómez J, Rodriguez A. An evaluation of the
results of a drug sample analysis. Bull Narc
1989; 41: 121-126.
14. Greer G, Tolbert R. Subjective reports of the
effects of MDMA in a clinical setting. J
Psychoactive Drugs 1986; 18: 319-327.
15. Greer G, Tolbert R. The therapeutic use of
MDMA. In: Peroutka SJ, ed. Ectasy: The clinical
pharmacological and neurotoxicological
effects of the drug MDMA. Boston: Kluwer
Academic Pub, 1990. pp 21-35.
16. Handly N. Toxicity, Amphetamine. Emedicine,
January 21, 2002.
17. Hernández-Cueto C, Luna A, Villanueva E. Niveles
de plomo en muestras de heroína. ¿Método
para la identificacion de diferentes muestras?.
Revista de Toxicología 1985; 2: 115-120.
18. Infante F, Domínguez E, Trujillo D, Luna A.
Metal contamination, in illicit samples of
heroin. J Forensic Sci 1999; 44: 110-113.
Luna, A. 107